Ipca Laboratories
Ipca Laboratories Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Ipca Laboratories Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Ipca Laboratories Ltd trades at a P/E of 35.16× and P/B of 4.98×.
Valuation
Profitability
Growth
Financial Health
Ipca Laboratories Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Ipca Laboratories Ltd, switchable between annual and quarterly views, consolidated or standalone.
Ipca Laboratories Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹40,313.6 Cr and reported EPS of ₹45.02.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,284 | 3,773 | 4,649 | 5,420 | 5,830 | 6,244 | 7,705 | 8,940 | 9,646 |
| Other Income | 42 | 58 | 67 | 63 | 67 | 126 | 125 | 93 | 174 |
| Total Income | 3,325 | 3,831 | 4,716 | 5,483 | 5,896 | 6,370 | 7,830 | 9,032 | 9,821 |
| Cost of Goods Sold (COGS) | 1,125 | 1,240 | 1,644 | 1,728 | 2,015 | 2,307 | 2,576 | 2,779 | 2,823 |
| Gross Profit | 2,159 | 2,533 | 3,005 | 3,692 | 3,815 | 3,938 | 5,129 | 6,161 | 6,824 |
| +Operating Expenses | 1,704 | 1,842 | 2,098 | 2,147 | 2,506 | 3,011 | 3,808 | 4,435 | 4,845 |
| EBITDA | 455 | 692 | 907 | 1,544 | 1,309 | 927 | 1,321 | 1,726 | 1,979 |
| +Non-Operating Expenses | 202 | 201 | 227 | 218 | 240 | 307 | 388 | 278 | 408 |
| Profit Before Tax (PBT) | 295 | 548 | 747 | 1,389 | 1,136 | 745 | 843 | 1,131 | 1,573 |
| +Tax Expense | 51 | 104 | 135 | 240 | 224 | 253 | 313 | 344 | 381 |
| Profit After Tax (PAT) | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 1,184 |
| Earnings Per Share (EPS) | 9.49 | 17.60 | 23.99 | 44.93 | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 |
| Diluted Shares Outstanding (Nos.) | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| +Additional Disclosures | 4,160 | 4,514 | 5,606 | 5,815 | 6,763 | 7,933 | 9,415 | 10,495 | 11,062 |
| Sales Growth % | — | 14.91 | 23.20 | 16.59 | 7.56 | 7.11 | 23.39 | 16.02 | 7.91 |
| YoY Sales Growth % | — | 14.91 | 23.20 | 16.59 | 7.56 | 7.11 | 23.39 | 16.02 | 7.91 |
| Material Cost % | 28 | 29 | 31 | 29 | 29 | 27 | 29 | 25 | 24 |
| Employee Cost % | 22 | 21 | 20 | 19 | 20 | 21 | 22 | 22 | 22 |
| Other Cost % | 29 | 28 | 25 | 21 | 23 | 28 | 27 | 27 | 28 |
| OPM % | 14 | 18 | 20 | 28 | 22 | 15 | 17 | 19 | 21 |
| Tax % | 17 | 19 | 18 | 17 | 20 | 34 | 37 | 30 | 24 |
| Profit Growth % | — | 84.70 | 36.48 | 89.07 | -22.03 | -46.17 | 9.17 | 50.16 | 50.75 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 277 | 509 | 696 | 1,335 | 1,077 | 665 | 964 | 1,328 | 1,560 |
Ipca Laboratories segment analysis: revenue and profit mix.
Disclosed business segments at Ipca Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Ipca Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Ipca Laboratories Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Ipca Laboratories Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Ipca Laboratories Ltd's investment case rests on 8 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Ipca Laboratories boasts a healthy Return on Equity (ROE) of 12.8% and Return on Capital Employed (ROCE) of 14.7%, indicating efficient use of shareholder investments and strong operational profitability.
The company demonstrates robust quarterly performance with sales growth of 10.3% and a significant 21.3% increase in quarterly profit, showcasing consistent market demand and effective management.
Ipca Labs maintains a low debt-to-equity ratio of 0.20, suggesting a manageable debt burden and a strong financial foundation. This is further supported by a healthy operating profit margin (OPM) of 19.1%.
Consistent annual profit after tax of ₹895 crore highlights the company's sustained profitability. Additionally, DII holding increased to 36.45% in Sept 2025, reflecting growing institutional confidence.
The growing global demand for pharmaceutical products, driven by an aging population and increasing healthcare awareness, presents a significant market expansion opportunity for Ipca Laboratories.
What can break it.
The company's Price-to-Earnings (P/E) ratio of 36.50 is relatively high compared to peers like Cipla (23.65) and Dr Reddy's (18.09), potentially indicating the stock might be overvalued.
Recent stock price movements show some volatility and declines, with a wide 52-week range from ₹1168 to ₹1758, indicating potential market uncertainty and significant price fluctuations.
Promoter holding stands at 44.7%, which is below 50%. While stable, this leaves room for potential future dilution or shifts in control, which could impact long-term shareholder value.
Despite a low debt-to-equity ratio, the absolute debt of ₹1363 crore is substantial. This figure requires careful consideration within the context of the company's overall financial health.
Ipca's Return on Capital Employed (ROCE) of 14.7% is notably lower than several peers, such as Torrent Pharma (27.05%) and Zydus Lifesci (24.31%), suggesting room for efficiency improvement.
What would change my mind.
Trim if P/E re-rates above 46. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 8.99. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Ipca Laboratories Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Ipca Laboratories Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Ipca Laboratories Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Ipca Laboratories Ltd — derived from the live tape, not yesterday's close.
Ipca Laboratories Ltd last traded at ₹1,583 with an intraday range of ₹1,568.6–₹1,640 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1583.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1768.60 | +185.60 | +11.72% |
| R3 | 1697.20 | +114.20 | +7.21% |
| R2 | 1668.60 | +85.60 | +5.41% |
| R1 | 1625.80 | +42.80 | +2.70% |
| PIVOT | 1597.20 | 14.20 | 0.90% |
| CURRENT | 1583.00 | — | — |
| S1 | 1411.60 | -171.40 | -10.83% |
| S2 | 1483.00 | -100.00 | -6.32% |
| S3 | 1525.80 | -57.20 | -3.61% |
| S4 | 1554.40 | -28.60 | -1.81% |
IPCALAB is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 1617 ~ 1640
Trading Below opening range, showing Bearishness
Ipca Laboratories Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Ipca Laboratories Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Ipca Laboratories Ltd stood at 52.8% of traded volume, against a 20-day average of 50.5%.
Ipca Laboratories announcements: results, concalls, ratings, M&A.
Filings Ipca Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Ipca Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 87 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
IPCA Laboratories Limited has informed the Exchange about Transcript
Copy of Newspaper Publication
IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Updates
IPCA Laboratories Limited has informed the Exchange regarding 'Revised Link for q4FY26 Conference Call to be held today'.
Dividend
IPCA Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 6…
Appointment
IPCA Laboratories Limited has informed the Exchange regarding re-appointment of Mr Mr. Prashant Godha as Executive Director of the company w.e.f.…
Investor decks & rating reports.
Ipca Laboratories insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Ipca Laboratories as reported to SEBI — buying and selling signals from the people who know the business best.
Ipca Laboratories insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Mrs. Usha M. Chandurkar | Insider | 18 Dec 2024 | sell | −40.00 L | ₹599.7 Cr | ₹1,499.25 |
Ipca Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Ipca Laboratories has declared, sequenced by announce and record date.
Ipca Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Ipca Laboratories Ltd: business, sector, key facts.
What Ipca Laboratories Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Ipca Laboratories Ltd operates in the Healthcare, listed as NSE: IPCALAB, BSE: 524494.
Ipca Laboratories Limited is a multinational pharmaceutical company with a long history, established in 1949 and headquartered in Mumbai, India. The company operates across a broad global footprint, distributing its products to India, Europe, Africa, the Americas, Asia, the CIS region, and Australasia. Their business model is vertically integrated, encompassing both the manufacture and marketing of their products.
A significant portion of Ipca's business involves the production and sale of Active Pharmaceutical Ingredients (APIs). These APIs are key components in the creation of various medications and are provided for a wide range of therapeutic applications. Specifically, Ipca focuses on APIs for anti-hypertensive, anti-malarial, diuretic, DMARD (disease-modifying antirheumatic drug), and anthelmintic treatments. This focus on APIs demonstrates Ipca's commitment to supplying crucial components to the broader pharmaceutical industry.
In addition to APIs, Ipca manufactures and markets a diverse portfolio of both generic and branded pharmaceutical formulations. These formulations cover an extensive range of therapeutic areas, indicating a wide-ranging approach to healthcare needs. These areas include allergy, oncology (anti-neoplastic/cancer drugs), arthritis, epilepsy, cardiology, diabetes, dermatology, gastroenterology, hematology, infectious diseases, neurology, pain management (neuropathic pain and NSAIDs), ophthalmology, orthopedics, psychiatry, respiratory ailments, rheumatology, and urology. Furthermore, they also offer nutraceuticals and probiotics, expanding their reach into complementary health products.
Ipca's global reach is a key component of its business strategy. The company actively exports its products worldwide, showcasing its ability to compete and succeed in international markets. This international focus suggests a commitment to serving global healthcare needs and a capacity to adapt to diverse regulatory and market landscapes. The breadth of its product offerings, from APIs to a wide variety of formulations, positions Ipca to participate in numerous segments of the pharmaceutical market.
Questions investors ask about Ipca Laboratories Ltd (IPCALAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Ipca Laboratories Ltd (IPCALAB)?
The current share price of Ipca Laboratories Ltd (IPCALAB) is ₹1,583. Today, the stock has declined by ₹30.60 (1.90%), trading in a range of ₹1,568.6 to ₹1,640. The stock opened at ₹1,629.8 with a trading volume of 1,31,987 shares.
02Is Ipca Laboratories Ltd stock a good investment for long-term?
Ipca Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹40,313.6 crores, P/E ratio of 35.16, ROE of 13.22%, and ROCE of 14.70%. The dividend yield stands at 0.37%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Ipca Laboratories Ltd stock?
The 52-week high price of Ipca Laboratories Ltd (IPCALAB) is ₹0, while the 52-week low is ₹0. Currently trading at ₹1,583, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Ipca Laboratories Ltd stock at the current price?
Whether to buy Ipca Laboratories Ltd stock at ₹1,583 depends on multiple factors. The stock is currently trading with a P/E ratio of 35.16 and P/B ratio of 4.98. Today's performance shows a loss of 1.90%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Ipca Laboratories Ltd and when is the next dividend?
Ipca Laboratories Ltd offers a dividend yield of 0.37%, which means for every ₹100 invested at the current price of ₹1,583, you can expect to receive approximately ₹0.37 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Ipca Laboratories Ltd?
Ipca Laboratories Ltd's key financial metrics include: P/E Ratio: 35.16, P/B Ratio: 4.98, ROE: 13.22%, ROCE: 14.70%, Dividend Yield: 0.37%, EPS: ₹45.02, Book Value: ₹317.89, and Debt-to-Equity: 8.49. The company's market cap stands at ₹40,313.6 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Ipca Laboratories Ltd stock performing today in the market?
Ipca Laboratories Ltd stock opened at ₹1,629.8 and is currently trading at ₹1,583, showing a decline of ₹30.60 (1.90%). The intraday high is ₹1,640 and low is ₹1,568.6. The trading volume stands at 1,31,987 shares, indicating moderate market participation today.
08What is the P/E ratio of Ipca Laboratories Ltd and what does it indicate?
Ipca Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 35.16, which means investors are willing to pay ₹35.16 for every ₹1 of earnings. With an EPS of ₹45.02, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Ipca Laboratories Ltd (IPCALAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy